文献速递细菌感染、耐药与抗菌药物

金黄色葡萄球菌菌血症抗生素治疗的当前临床实践:五国欧洲调查结果

Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

该调查通过ESGAP网络于2021年7月至11月在克罗地亚、法国、希腊、荷兰和英国发放网络问卷,评估感染病专家、临床微生物学家和内科医生对金黄色葡萄球菌菌血症抗生素治疗的实践差异。1687人打开链接,677人(40%)至少回答一题。结果显示各国及国内在口服降阶梯治疗、口服药物选择、疗程和18F-FDG-PET/CT使用上存在相当大的实践差异。

要点

  • 对于MSSA和MRSA菌血症,分别有98%和94%的受访者偏好初始单药治疗。
  • 对于不可移除感染假体的SAB患者,80%至90%的受访者会使用利福平作为治疗的一部分。
  • 骨关节感染中65%-77%的受访者考虑口服降阶梯治疗,而血管内感染仅12%-32%。

核心结论

  • 该五国欧洲调查显示各国间及国内在SAB抗生素管理上存在相当大的临床实践差异,尤其在口服降阶梯治疗、口服抗生素选择、疗程和18F-FDG-PET/CT使用方面。
  • 医生使用不同的标准做出治疗决策,因为临床试验证据常常缺乏。
  • 这些实践差异领域可用于优先安排未来研究以进一步改善SAB诊疗。

研究设计与样本

  • 通过ESGAP网络在克罗地亚、法国、希腊、荷兰和英国发放网络问卷调查,时间为2021年7月至2021年11月。
  • 调查对象为感染病专家、临床微生物学家和内科医生。
  • 1687名受访者打开调查链接,其中677名(40%)至少回答了一个问题。

主要发现

  • 对于MSSA和MRSA菌血症,分别有98%和94%的受访者偏好初始单药治疗。
  • 对于SAB且不可移除感染假体的患者,80%至90%的受访者会使用利福平作为治疗的一部分。
  • 对于骨关节感染,65%-77%的受访者会考虑口服降阶梯治疗,但对于血管内感染仅12%-32%会考虑。
  • 受访者对不同感染灶的SAB推荐了广泛不同的治疗时长。
  • 总体48%的受访者表示使用18F-氟脱氧葡萄糖正电子发射断层扫描/CT(18F-FDG-PET/CT)指导抗生素治疗时长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine clinical practice variation and identify knowledge gaps in antibiotic treatment of Staphylococcus aureus bacteraemia (SAB). METHODS: A web-based survey with questions addressing antibiotic treatment of SAB was distributed through the ESGAP network among infectious disease specialists, clinical microbiologists and internists in Croatia, France, Greece, the Netherlands and the UK between July 2021 and November 2021. RESULTS: A total number of 1687 respondents opened the survey link, of whom 677 (40%) answered at least one question. For MSSA and MRSA bacteraemia, 98% and 94% preferred initial monotherapy, respectively. In patients with SAB and non-removable infected prosthetic material, between 80% and 90% would use rifampicin as part of the treatment. For bone and joint infections, 65%-77% of respondents would consider oral step-down therapy, but for endovascular infections only 12%-32% would. Respondents recommended widely varying treatment durations for SAB with different foci of infection. Overall, 48% stated they used 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG-PET/CT) to guide antibiotic treatment duration. Persistent bacteraemia was the only risk factor for complicated SAB that would prompt a majority to extend treatment from 2 to 4-6 weeks. CONCLUSIONS: This survey in five European countries shows considerable clinical practice variation between and within countries in the antibiotic management of SAB, in particular regarding oral step-down therapy, choice of oral antibiotic agents, treatment duration and use of 18F-FDG-PET/CT. Physicians use varying criteria for treatment decisions, as evidence from clinical trials is often lacking. These areas of practice variation could be used to prioritize future studies for further improvement of SAB care.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Buis DTP, Prins JM, Betica-Radic L, et al. Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries. J Antimicrob Chemother. 2022. PMID: 35869753. doi:10.1093/jac/dkac237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。